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Switzerland; 6Department of Head and Neck Surgery, University Hospital of Geneva, Geneva, SwitzerlandSynthetic microRNA (miRNA) minigenes (SMIGs) have a
major potential for molecular therapy; however, their optimal
architecture still needs to be determined. We have previously
optimized the stem structure of miRNA hairpins for efﬁcient
gene knockdown. Here, we investigate the overall architecture
of SMIGs driven by polymerase II-dependent promoters.
When miRNA hairpins were placed directly behind the
promoter, gene knockdown was inefﬁcient as compared with
constructs containing an intercalated sequence (“spacer”).
Spacer sequence was relevant for knockdown efﬁciency and
concatenation potential: GFP-based sequences (even when
truncated or including stop codons) were particularly efﬁcient.
In contrast, a spacer of similar length based on a CD4 intronic
sequence was entirely inefﬁcient. Spacer sequences inﬂuenced
miRNA steady-state levels without affecting transcript stabil-
ity. We demonstrate that with an optimized spacer, up to ﬁve
concatenated hairpins targeting two different genes are efﬁ-
ciently expressed and able to knock down their respective tar-
gets. Transplantation of hematopoietic stem cells containing
a CCR5 knockdown SMIG demonstrated a sustained in vivo
efﬁcacy of our approach. In summary, we have deﬁned features
that optimize SMIG efﬁciency. Based on these results, opti-
mized knockdown of genes of interest, such as the HIV co-re-
ceptor CCR5 and the NADPH oxidase subunit p22phox, was
achieved.Received 6 June 2017; accepted 1 December 2018;
https://doi.org/10.1016/j.omtn.2018.12.004.
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The discovery and characterization of microRNA (miRNA) genes
and their regulatory mechanisms not only provided a novel under-
standing of physiological regulation of gene expression,1 but also
opened new possibilities for miRNA-based therapeutics.2 The center-
piece of miRNA genes is a hairpin that ultimately will give rise to a
ribonucleoprotein complex,3 which knocks down expression of target
genes through identiﬁcation and destruction of its transcript.4
Structural elements of the hairpin provide a signal for processing
by DROSHA and DICER,5 leading to formation of an 20–23 bp
mature miRNA duplex.1 The functional strand of mature miRNAMolecular The
This is an open access article under tduplex is incorporated into the RNA-induced silencing complex
(RISC) complex,3 which facilitates target mRNA recognition and
eventually gene knockdown.4 Synthetic miRNAs as well as by-prod-
ucts of the miRNA pathway, such as short hairpin RNAs (shRNAs)
and small interfering RNAs (siRNAs), are now commonly used tools
in molecular biology. However, the pathway has not lived up to its
therapeutic potential.2,6 siRNAs are most advanced in clinics6; how-
ever, they are short-lived in vivo, and their transient effect would
require repeated in vivo delivery for efﬁcient long-term gene correc-
tion.7 shRNAs, which bypass DROSHA processing, may overload
the cytoplasm with double-stranded RNA and hence lead to toxicity
by obstructing the natural miRNA pathway.8,9 Synthetic miRNAs
mimic the natural pathway and should therefore overcome the above
limitations,10 but their use might be limited because of a relatively
weak knockdown activity of miRNA, as compared with shRNAs.11
Lentiviral vectors can be used to express synthetic miRNA genes
because genomic integrations of the transgene and long-term expres-
sion in recipient cells have to date been shown to be safe in
patients.12,13 However, further research is needed to optimize
knockdown by synthetic miRNA genes to the extent that allows efﬁ-
cient therapeutic correction of pathological gene expression.
The architecture of synthetic miRNA genes, including the tridimen-
sional structure of the hairpin, is of crucial importance for the knock-
down efﬁciency.14,15 In a previous study, we demonstrated that the
length of the lower stem is crucial for efﬁcient processing byrapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The Author(s). 351
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Effect of a Spacer Sequence on Polymerase II Promoter-Driven miRNA Knockdown
(A) Schematic representation of miRNA-based minigenes used in this experiment. All hairpins were designed to target CCR5. Two different polymerase II-dependent
promoters (ubiquitin C and elongation factor 1 short) drive miRGE expression (single or triple hairpin) with or without the GFP sequence as spacer. The position of the spacer,
either in 50 or in 30 of the promoter, was also investigated. (B) Constructs expressed with a ubiquitin C promoter or elongation factor 1 short promoter were transduced at
0.2 MOI in HeLa cells expressing CCR5. Flow cytometry determination of CCR5 expression in the transduced population (mCherry+) versus the untransduced population
(mCherry): wild-type (WT) HeLa cells (double negative), HeLa R5 cells (CCR5-positive). R5 + Ctrl mCherry vector; R5 + single mirGE hairpin with GFP spacer. (B0) Mean APC
fluorescence values in the transduced (red) and untransduced (blue) populations were used to calculate the miRNA-mediated CCR5 knockdown. (C) Bar graph showing the
(legend continued on next page)
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available, resulting in increased target gene knockdown. However,
the architecture of the miRNA gene is not limited to the hairpin struc-
ture. Other important elements include promoters and nucleotide se-
quences not directly linked to the hairpin (which we will refer to as a
“spacer” throughout the text). miRNA genes are most of the time
driven by polymerase II-dependent promoters, which allows tissue-
speciﬁc and/or inducible expression.16–19 The presence of a spacer ap-
pears to enhance knockdown efﬁciency20; however, it is not known
whether sequence length or other biophysical parameters of the
spacer are of importance.
Natural miRNA genes occur in a concatenated form; their architec-
ture consists of an arrangement of several hairpins under the control
of a single promoter.21 Such concatenation is potentially a powerful
tool for biotechnology, because multiple genes may be targeted simul-
taneously and knockdown efﬁciency may be increased by employing
multiple miRNAs per target gene.22,23 To date, several concatenating
strategies have been developed, including the use of natural polycis-
tronic miRNA backbones,21,22,24,25 the concatenation of several
synthetic miRNA hairpins (e.g., derived from miR-15515 or derived
from miR-1614), or the use of DROSHA-independent intronic
miRNA (mirtrons).26,27 However, depending on the synthetic mini-
gene architecture, an additive effect of miRNA concatenation when
targeting the same gene is not always observed28 or has a limited
effect.29 For example, absence of additive effects of hairpin concate-
nate versus the single hairpin construct was reported using a synthetic
miRNA gene with the Blasticidin resistance gene as a spacer. Another
study using a different miRNA gene architecture, namely a cytomeg-
alovirus (CMV) promoter and a DsRed spacer, investigated the effect
of the position of hairpin within the concatenate on the knockdown
efﬁciency. The authors reported a loss of activity of hairpins when
located beyond the fourth position in the concatenate.29 Another
interesting element of miRNA architecture is the arrangement of
several hairpins under the control of a single promoter. This occurs
in natural miRNAs21,22; however, such a concatenation is also a
potentially powerful tool for biotechnology.23
Using a previously described miRGE miRNA hairpin design,14 we
here further investigated the structural features of synthetic miRNA
minigenes (SMIGs) to efﬁciently achieve multi-target gene knock-
down. Our results provide a ﬁrst demonstration that the spacer
sequence, rather than spacer length itself, is crucial for efﬁcient
miRNA expression. In addition, the spacer sequence plays an impor-
tant role for concatenation efﬁciency. Interestingly, the knockdown
potency of a spacer with a single hairpin was not predictive of its
concatenation efﬁciency. We show that with an optimal spacer
sequence, concatenates with up to ﬁve efﬁcient hairpins can be
constructed, and that different genes can be targeted from a singlerelative expression of CCR5 with the UBI promoter constructs. (D) Histogram show
Concatenation efficiency (E) of the different constructs as calculated on the bar graph
(efficiency is 0%). If E = 3, perfect additive effect of the hairpin is observed in the conca
experiments.SMIG. We also demonstrate that using the optimized SMIG architec-
ture, efﬁcient knockdown of clinical relevant targets, such as CCR5
and NOX3, can be achieved.
RESULTS
A Spacer Sequence Is Required for Polymerase II Promoter-
Driven miRNA-Mediated Target Gene Knockdown
It has previously been suggested that a spacer sequence, either located
between the promoter and the miRNA hairpin sequences or on the 30
end of the miRNA sequence, was able to enhance artiﬁcial miRNA-
based knockdown, driven by polymerase II-dependent promoters.20,23
Moreover, concatenation of hairpins has previously been shown to
exhibit an additive effect on the target gene knockdown.14,23 To opti-
mize the miRGE-based knockdown and better understand the role of
the spacer, we placed theGFP sequence either on the 50 or on the 30 end
of the miRGE hairpin sequences in a lentiviral vector (Figure 1A).
HeLa cells expressing CCR5 (R5 cells) were transduced at an MOI
of 0.2 to reduce statistical probabilities of having more than one
copy of transgene per cell (Figure 1B). Both single and a triple hairpins
targetingCCR5were used.We studied two different polymerase II-de-
pendent promoters: the ubiquitin promoter (UBI) and a spliced
version of the elongation factor 1 promoter (elongation factors).30
When the UBI promoter was used, absence of the spacer entirely
precluded CCR5 knockdown, even when three hairpins were used
(Figure 1C). The efﬁcacy of the spacer depends on its position. With
the spacer between the promoter and the miRNA, an efﬁcient CCR5
knockdown was observed with a single hairpin, which was markedly
enhanced with a concatenated triple hairpin construct. When the
spacer was put in the 30 position of themiRNA gene, the single hairpin
showed a decreased CCR5 knockdown efﬁciency, whereas the
increased knockdown effect of the concatenate was entirely lost (Fig-
ures 1C and 1E). The situation was slightly different for the elongation
factors promoter (Figure 1D). The efﬁcacy of a single hairpin did not
depend on the presence of a spacer, but no additive effect of the triple
concatenate was observed in the absence of a spacer (Figure 1E). In
contrast, with the spacer between the promoter and the hairpins, a
maximal effect of the triple concatenate was achieved, whereas a less
pronounced effect was observed with the spacer in 30.
Together, the data demonstrate that a spacer sequence, preferentially
located in 50 of the miRNA, is required to drive efﬁcient knockdown
via two types of polymerase II-dependent promoters. Interestingly,
the spacer is also required for additive effects of the hairpin concate-
nation (Figure 1E).
Efficiency of miRNA-Based Knockdown Depends on the Spacer
Sequence
To further understand the role of the spacer sequence and to opti-
mize knockdown efﬁciency of the vector, we assessed the potency ofing the relative expression of CCR5 with the EF1 short promoter constructs. (E)
. If E = 1, absence of additive effect is observed with the concatemerized hairpins
tenate (efficiency is 100%). Data represent the mean ± SEM of three independent
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Figure 2. Efficiency of miRNA-Based Knockdown
Depends on the Nucleotide Sequence of the Spacer
(A) Single miRGE hairpin-based constructs targeting
CCR5 were designed with different spacers derived either
from coding sequences of GFP, MGST-2 (microsomal
glutathione S-transferase-2), dNGFR (truncated nerve
growth factor receptor), HO-1 (heme oxygenase-1), and
H2B (histone 2B), or from noncoding sequences (first
intron of the CD4 gene = iCD41) and transduced at
0.2 MOI in HeLa R5 cells. Histogram showing the
expression of CCR5 in the transduced population relative
to the untransduced population, as assessed by FACS
immunostaining. (B and C) miRGE constructs were de-
signed with truncated forms of GFP (GFP1 and GFP2) (B)
or the first intron of CD4 (iCD42 and iCD43) (C) and
transduced at 0.2MOI in HeLa R5 cells. Histograms show
the level of CCR5 expression of the transduced popula-
tion relative to the untransduced population. Data repre-
sent the mean ± SEM of three independent experiments.
Molecular Therapy: Nucleic Acidsseveral coding and noncoding sequences (Figure 2A; Table S1). We
generated ﬁve miRGE minigenes with coding sequences as spacers:
GFP, microsomal glutathione S-transferase-2 (MGST2), truncated
nerve growth factor receptor (dNGFR), heme oxygenase-1
(HO-1), and histone 2B (H2B) cDNAs. We also used the ﬁrst intron
of the CD4 gene, iCD4, as a noncoding spacer sequence. Lentivec-
tors carrying the respective minigenes were used to transduce HeLa
R5 cells. We observed a signiﬁcant knockdown of the CCR5 protein
in the transduced population of cells with all coding sequences
(MGST, LNGFR, HO-1, and H2B spacers). The GFP sequence
spacer resulted in the highest knockdown of CCR5. The worst per-
forming spacers were iCD4 and H2B (<10% knockdown), whereas
the other coding sequences resulted in an intermediate efﬁciency
(Figure 2A).
In an attempt to identify speciﬁc regions within spacer sequences that
have an effect on the knockdown efﬁciency, truncated forms of GFP
(GPF1, GFP2) and of the iCD4 (iCD42, iCD43) were designed (Fig-
ures 2B and 2C). Remarkably, the activity of the truncated GFP1 and
GFP2 was comparable with full-length GFP (Figure 2B). The situation
was different for the CD4 intron, where the shorter amplicons (iCD42
and iCD43) resulted in a moderate but signiﬁcant knockdown of
CCR5 (Figure 2C). However, these truncated CD4 ﬁrst intron se-
quences were still inefﬁcient spacers when compared with sequences
of similar length (GFP1 or GFP2) (Figures 2B and 2C). These results
demonstrate that the spacer activity does not simply depend on the
length, but that the nucleotide sequence also seems to determine its354 Molecular Therapy: Nucleic Acids Vol. 14 March 2019efﬁciency. We did not observe a correlation be-
tween the predicted minimum free energy
(MFE) of spacers and the knockdown efﬁciency
(Figure S1A). This raises the possibility that the
secondary structure of the spacer is not a crucial
element. We assessed GC content of the spacer
sequences and found that spacers with higherGC content tended to correlate with the higher knockdown efﬁciency
(Figure S1B).
The Spacer Sequence Determines the Additive Effects of miRNA
Hairpin Concatenation
To conﬁrm the role of the spacer sequence in the concatenation
potency of the vector, multi-hairpin constructs were designed with
different spacers: GFP, GFP2, MGST2, or H2B (Figure 3A). When
the GFP or GFP2 sequence was used as a spacer, the concatenation
of three hairpins dramatically enhanced CCR5 knockdown compared
with a single hairpin construct (from 60% to 85% CCR5 knockdown)
(Figures 3B and 3C). When MGST2 was used as a spacer, substan-
tially different results were obtained. As illustrated in Figure 2A,
with a single hairpin, the MGST2 sequence had a good spacer activity,
albeit not as potent as the GFP sequence. However, with MGST2 as
the spacer, no additive effect of a three-hairpin concatenation was
observed (concatenation efﬁciency close to 1) (Figure 3C). Thus, we
observe a dissociation between the spacer potency with a single
hairpin, as compared with the concatenation activity. Although the
former is in a comparable range for GFP and MGST2, the latter is
virtually absent with MGST2 as a spacer (Figure 3C). The opposite
was observed with H2B as a spacer: a rather poor knockdown was
observed with a single hairpin (10%), whereas there was an
improved concatenation effect as judged by the CCR5 knockdown
with the triple hairpin construct (40% knockdown) (Figures 3B and
3C). To investigate whether this observation also applies to hairpins
targeting genes other than CCR5, we constructed triple hairpin
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Figure 3. Efficient Concatemerization of Hairpins
Depends on the Nucleotide Sequence of the Spacer
(A) The efficiency of MGST2, H2B, and GFP as spacer
was assessed on miRGE hairpin concatenation (three
hairpins concatenate) in HeLa-expressing CCR5 cells. (B)
Histogram shows the level of CCR5 expression of the
transduced population relative to the remaining un-
transduced population for the GFP spacer (black bars),
the second part of GFP (GFP2) (hatched), MGST2 spacer
(dark gray bars), and the H2B spacer (clear gray bars). (C)
The bar graph shows the concatenation efficiency for the
triple hairpin constructs, as calculated with the formula in
Figure S3. For the calculation of the concatenation effi-
ciency, CCR5 knockdown with a single miRGE hairpin
(knockdown potency [KP]) and with a triple miRGE
concatenate (concatenation potency [CP]) were consid-
ered. (D and E) The potency of MGST2 and GFP as
spacers was also compared in a triple hairpin concate-
nate targeting the NADPH oxidase subunit p22phox.
mRNA level of p22phox as assessed in the promyelocytic
leukemia cell line PLB985 by qPCR (D) and on NADPH
oxidase activity by Amplex red assay (E). Data represent
the mean ± SEM of three independent experiments.
www.moleculartherapy.orgSMIG targeting the NOX subunit p22phox (CYBA) with eitherMGST2
or GFP as spacer sequences (Figures 3D and 3E; see also Figure S1).
These constructs were used to transduce the promyelocytic leukemia
cell line PLB-985, which upon differentiation toward a neutrophil-
like phenotype expresses all phagocyte NADPH oxidase subunits
(including NOX2 and p22phox/CYBA) and produces reactive oxygen
species (ROS) through this NADPH oxidase. We observed a 50%
decrease in the CYBA mRNA level using the MGST2 spacer-triple
hairpin constructs, whereas with a GFP spacer CYBA mRNA knock-
down was >80% (Figure 3D). These results corroborate our previous
observation with hairpins targeting CCR5. We also looked at func-
tional activity of the phagocyte NADPH oxidase, namely ROS gener-
ation (Figure 3E). The production of ROS was inhibited by 60% with
the GFP-triple hairpin concatenate targeting p22phox. In contrast, by
replacing GFP with MGST2 as a spacer, ROS production was in-
hibited by no more than 20%. These data conﬁrm that, although
efﬁcient knockdown is seen with a single hairpin, the MGST2 spacer
has poor concatenation activity (Figure 3C; Figure S2). These exper-
iments demonstrate that the spacer sequence is not only required for
the knockdown efﬁciency with a single hairpin but is also required for
the additive concatenation effect: the concatenation potency. ThusMolecular Thfar, the GFP spacer exhibited the most effective
combination of knockdown and concatenation
(Figures 3B and 3C).
Translation-Independent Activity of the
GFP Spacer in Cell Lines and Tissue
Explants
Among the tested candidates, the GFP sequence
was most efﬁcient as a spacer, both with respect
to knockdown potency with a single hairpin andconcatenation potency. Other coding sequences also yielded some
signiﬁcant knockdown activity, while the CD4 intron was inactive.
To test whether protein translation of GFP was required for optimal
functioning of the SMIG, we designed a construct harboring stop co-
dons in each possible reading frame (Figure 4A). As predicted, no
ﬂuorescence was detected in the cells transduced with stopGFP
(Figure 4B). The CCR5 knockdown achieved with the stopGFP spacer
was comparable with knockdown with the standard GFP spacer
(50% with a single hairpin construct). These results are relevant
for two reasons: (1) they refute the hypothesis that protein translation
of the spacer is important for the function of SMIG; and (2) they
provide highly efﬁcient spacer, which does not lead to translation
of the xenogene GFP and is therefore compatible with a future
clinical use.
To demonstrate the therapeutic potential of the optimized SMIG
including the stopGFP spacer, we investigated a potential clinical
application, namely knockdown of the inner ear NADPH oxidase
NOX3. This ROS-producing NADPH oxidase has been shown to
be a relevant source of ROS leading to inner ear damage, and it is
hence an attractive knockdown target for inner ear protection.31erapy: Nucleic Acids Vol. 14 March 2019 355
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ED
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Figure 4. Untranslated Spacer Supports miRNA Minigene Architecture and Knockdown of Inner Ear Target Genes
(A) Design of the stopGFP spacer, harboring stop codons in all possible reading frames of the GFP cDNA in 30 of the initiation codon (ATG). (B) HeLa R5 cells were transduced
at >1MOI with both coding and noncoding forms of GFP. FACS histograms show the fluorescence of GFP in transduced cells. The GFP fluorescence of cells transduced with
the stopGFP construct was comparable with the control (non-transduced HeLa cells). (C) The spacer activity of stopGFP sequence was also assessed by FACS on CCR5
expression after 0.2 MOI transduction in HeLa R5 cells. The histogram shows the expression of CCR5 of the transduced population relative to the untransduced population
as assessed by FACS immunostaining. Data represent the mean ± SEM of three independent experiments. (D) Organotypic culture of newborn rat cochlear explants
transduced with increasing amounts of stopGFP triple miRGE hairpin concatenate targeting p22phox (106–107 vector particles). Hair cells are stained for myosin 7a (in green)
and efficiently transduced cells express the marker gene mCherry (red). After 5 days in vitro, expression of the viral gene GAG (E) and p22phox (F) was assessed by qPCR. TU,
transducing units.
Molecular Therapy: Nucleic AcidsFor this purpose, we designed a triple miRGE concatenate, targeting
the NOX3 subunit p22phox, under the control of the UBI promoter,
and with stopGFP as a spacer. To identify transduced cells, the
mCherry coding sequence under the control of the phosphoglyc-
erate kinase 1 (PGK) promoter was also included in the construct.
Using this construct, we transduced newborn rat cochlear explants
(Figure 4D). Using RT-PCR to detect and quantify the lentiviral
GAG gene, we conﬁrmed a dose response for vector transduction
(Figure 4E). Transduced cells could also be identiﬁed by mCherry
red ﬂuorescence (Figure 4D; green ﬂuorescence is a marker for
hair cells). As seen in this picture, only a minority of hair cells356 Molecular Therapy: Nucleic Acids Vol. 14 March 2019were transduced with the vector under our experimental conditions.
Despite this suboptimal transduction efﬁciency, results showed a
dose-dependent decrease in p22phox mRNA, conﬁrming the efﬁ-
ciency of the miRGE vector with a second clinically relevant target
gene (Figure 4F).
Sustained miRNA-Mediated Knockdown of CCR5 in Circulating
Leukocytes Derived from Human Hematopoietic Stem Cells
To further demonstrate the in vivo efﬁcacy and the therapeutic
potential of the optimized SMIG including the stopGFP spacer,
we investigated another promising clinical application, namely
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Figure 5. Optimized Minigene Architecture
Allows Sustained In Vivo Knockdown of CCR5 in
Circulating Cells
(A) Six NGS newborn mice were engrafted with 260,000
human CD34+ hematopoietic stem cells (HSCs),
following transduction with triple hairpin concatenate
targeting CCR5. At the age of 28 weeks, blood was
harvested for analysis of CCR5 expression. (B) FACS
plots showing CD4+ T cells from mice transplanted with
non-transduced HSC (left) or transplanted with stopGFP-
777 transduced HSC (center). Right plot shows CD4+
T cells stained with irrelevant antibody (untransduced
HSC). mCherry+ cells indicate effectively transduced
cells. (C) Histogram showing expression level of CCR5 in
transduced (mCherry+) and remaining untransduced
(mCherry) CD4 T cell population for a single transplanted
mouse, relative to irrelevant antibody (isotype). Cells on
the right of the dotted line represent high CCR5-
expressing CD4 T cells. (D) Comparison of the CCR5
expression level in high CCR5 CD4+ T cells population
in five engrafted mice. Untransduced ctrl stands for
mice engrafted with non-transduced human CD34+ cells
(n = 3).
www.moleculartherapy.orgknockdown of the HIV co-receptor CCR5 in vivo (Figure 5). For
this purpose, we transduced human CD34+ hematopoietic stem cells
(HSCs) with a triple miRGE concatenate, targeting CCR5, under the
control of an elongation factors promoter, and with stopGFP as a
spacer. To identify transduced cells, the mCherry coding sequence
under the control of the PGK promoter was also included in the
construct. After transduction, HSCs were engrafted in NGS (NOD
scid gamma) mice following irradiation (Figure 5A), achieving an
engraftment rate varying between 12.4% and 44%, after 23 weeks
(Figure S4). 28 weeks following the engraftment, CCR5 expression
was investigated in the circulating blood (Figure 5; Figure S5).
The results revealed two kinds of CD4+ T cells with respect to
CCR5 expression in untransduced control and mCherry-negative
cells (Figures 5B and 5C). The proportion of high CCR5-expressing
CD4 T cells varied from less than 10% to more than 50% with an
average close to 25% in ﬁve of the six engrafted animals (Figure 5D,
see mCherry and untransduced ctrl). Note that in one of the six
engrafted animals, the high CCR5 CD4 T cells population was virtu-
ally absent and therefore not taken into account in Figure 5D.
Importantly, we observed a dramatic decrease of the CCR5 expres-
sion level in the mCherry+ transduced population (Figure 5D,
mCherry+).Molecular ThThe Spacer Sequence Regulates the
Steady-State Levels, but Not theHalf-Life of
miRGE
To better understand the mechanisms of
spacer activity, we designed PCR primers to
quantify unprocessed miRGE hairpins (pri-
miRGE) (Figure 6A) or the mature miRGE
(Figure 6E). As seen in Figures 6B and 6C,
relative expression of the miRGE pri-miRNAwas signiﬁcantly stronger in cells transduced with the stopGFP
spacer than in the cells transduced with the MGST-2 or NGFR-
based vector. Note that miRGE expression was below the detection
threshold with the CD4 ﬁrst intron as spacer, as also seen in the
absence of a spacer. To investigate whether this increase in the
steady-state levels of miRGE was due to a prolonged half-life of
the transcript, HeLa R5 cells were treated with actinomycin D for
different time periods to block transcription (Figure 6D). mRNA
was harvested and miRGE expression levels assessed by qPCR of
the pri-miRGE at the different time points. Results showed an esti-
mated mirGE half-life of approximately 30 min with the stopGFP
spacer (Figure 6D), similar to that seen with the NGFR and
MGST spacers. The steady-state level of the mature miRGE demon-
strated that stopGFP spacer allows the best expression of the mature
miRGE (Figure 6F). This observation was also valid when
comparing stopGFP and MGST2 spacers with triple hairpin concat-
enates (Figure 6G). Interestingly, both levels of precursor and
mature miRGE were similarly impacted by the spacer sequence.
These results strongly suggest that spacer activity is not linked to
stability of miRNA transcript nor processing. Our results would
rather be compatible with a mechanism where the spacer is relevant
for the transcription of the SMIG.erapy: Nucleic Acids Vol. 14 March 2019 357
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Figure 6. The Spacer Sequence Regulates the
Steady-State Levels of Mature miRNA
HeLa cells expressing CCR5 were transduced with single
hairpin vector with GFP, LNGFR, MGST2, or iCD41 as
spacers. (A) Unprocessed (pri-miRGE) or (E) mature
miRGE level was assessed by qPCR using primers
matching the flanking region of pri-miRGE (F1-R1) or the
targeting strand of the mature miRGE (F2-R2). (B)
Representative qPCR amplification plot of unprocessed
miRGE level with GFP, NGFR, and MGST2 as spacers.
Note that without spacer or with iCD41 as spacer, miRGE
level was below detection threshold. GAPDHwas used as
housekeeping gene. DRn of 0.2 was defined as the
threshold (red line). (C) Bar graph shows the relative level
of unprocessed miRGE as averaged from three inde-
pendent experiments. The highest value of miRGE
expression, normalized to 1.0, corresponds to a cycle
threshold (Ct) value of 28.1 ± 0.3. (D) Transcription was
blocked with actinomycin D at different time points
(0–240 min), and effect of the spacer was assessed on
unprocessed miRGE half-life. Graph shows the relative
miRGE decay over time, and half-life for each spacer is
displayed in the table. (E–G) Comparison of the steady-
state level of the mature miRGE (E) as assessed by qPCR
from HeLa cells transduced with single hairpin (F) or triple
hairpin concatenates (G) with different spacers. Data
represent the mean ± SEM of three independent experi-
ments. BT, below detection threshold.
Molecular Therapy: Nucleic AcidsMaximizing Concatenation and Achieving Multi-target Gene
Knockdown
The concept of successive cloning of miRNA hairpins was previously
demonstrated with a CMV promoter-mediated miRNA-based lenti-
vector.23 Sun et al.23 successively cloned up to three miRNA hairpins,
expressed in a lentivector system with a single CMV promoter, and
reported that knockdown of the target gene was proportional to the
number of hairpins. We previously conﬁrmed these observations
when using a UBI promoter to drive expression of up to three miRGE
hairpins designed to target CCR5.14 To further investigate the possi-
bility of a multi-target gene knockdown vector with a single pro-
moter-driven miRNA cluster, a fourth and a ﬁfth mirGE hairpin,
either targeting CCR5 or a second target gene (GFP in this case),
was added to the triple CCR5 construct (Figure 7A). Concatenation
of the hairpins led to a signiﬁcant increase of the mature miRGE358 Molecular Therapy: Nucleic Acids Vol. 14 March 2019steady-state level as a function of the number
of hairpins present in the concatenate (Fig-
ure 7B). Interestingly, the addition of a fourth
hairpin targeting CCR5, while leading to the
highest mature miRGE level, did not provide
additional decrease in CCR5 expression
compared with the triple hairpin construct,
arguing for a possible saturation of the CCR5
target sites with the miRGE (Figure 7C). On
the other hand, when we replaced the fourth
hairpin with a hairpin targeting GFP, not onlydid CCR5 knockdown remain at its maximum level (90%), but
there was also a signiﬁcant decrease in GFP ﬂuorescence (Figure 7C).
Thus, while the hairpin in the fourth position did not further enhance
CCR5 knockdown, it was clearly still efﬁciently processed, as wit-
nessed by the GFP knockdown (Figure 7D) and the mature
miRGE-GFP steady-state level (Figure 6E). Interestingly, a ﬁfth
hairpin targeting GFP displayed similar knockdown efﬁciency and
level of mature miRGE as the fourth, still without affecting knock-
down of the CCR5. More importantly, miRGE_GFP steady-state
levels as well as GFP knockdown mediated by the fourth or the ﬁfth
miRGE hairpins was comparable with knockdown achieved with a
single miRGE hairpin targeting GFP. Thus, with UBI as promoter
and stopGFP as spacer, there was no loss of activity with up to ﬁve
concatenated hairpins. However, the efﬁciency of the ﬁve-hairpin
concatenation strongly depended on the spacer. Indeed, the use of
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Figure 7. Optimized miRNA Minigene Architecture
Allows Maximal Hairpin Concatenation and
Efficient Multi-target Knockdown
(A) Efficiency of the stopGFP triple concatenate targeting
CCR5 (mirGE 7-7-7) was compared with constructs
harboring a fourth or a fifth hairpin either targeting CCR5
or a second target: GFP. Bar graphs show the steady-
state level of the mature miRGE targeting CCR5 (7) (B) or
targeting GFP (G) (D), as assessed by qPCR and the
ability of these constructs to knock down CCR5 expres-
sion (C) or GFP expression (E) in HeLa cells. Vectors
expressing a single miRGE hairpin targeting CCR5 or GFP
were used as controls. (F) When replacing the stopGFP
with MGST2 as spacer, activity of the fourth and the fifth
hairpin was decreased, as compared with the single
miRGE hairpin control (miRGFP) or the fifth hairpin of the
stopGFP construct. Data represent the mean ± SEM of
three independent experiments.
www.moleculartherapy.orgMGST2 as spacer led to a dramatic decrease of the fourth and ﬁfth
hairpin GFP knockdown potency (Figure 7F). These data demon-
strate that optimized SMIG architecture allows for efﬁcient multi-
target gene knockdown upon a single promoter-driven, multi-hairpin
construct.
DISCUSSION
Wereport in this study the development and optimization of SMIGs for
therapeutic gene knockdown. We analyzed knockdown efﬁciency by
single hairpins as well as the concatenation potential. For both features,Molecular Ththe insertion of a spacer within the SMIG was
crucial. Nucleotide sequence, rather than length
of the spacer, was a key feature for optimized
knockdown activity. The spacer determined
miRNA steady-state levels, rather than transcript
stability. The relevance of these modiﬁcations
was conﬁrmed by in vivo experiments demon-
strating sustainedmiRNA-mediated knockdown
of CCR5 in HSC-derived leukocytes.
Although the expression of very short RNAs,
such as shRNAs, is usually driven by polymerase
III-dependent promoters, the expression miR-
NAs, either natural or synthetic, is usually driven
through polymerase II promoters.16 Polymerase
III-driven shRNA expression leads to very high
transcript levels32 and is associated with satura-
tion of the miRNA processing pathway leading
to decreased levels of processed endogenous
miRNAs and various toxicities.9 These problems
have not been reported with polymerase II-de-
pendent expression of SMIG.Another advantage
of polymerase II-dependent promoters is the
possibility for tissue-speciﬁc and inducible
expression.17,19,33 However, the main limitationof previously described synthetic miRNAs was the relatively low
knockdown efﬁciency. In our study, we compared two different
polymerase II-dependent promoters, namely the UBI and the EF1
short promoter. Although the two promoters impacted differently on
SMIG knockdown efﬁcacy (see below), in general, most of the results
described below are valid when using either promoter.
One of the key ﬁndings of our study is the complex role of a so-called
spacer. The need for a spacer in the SMIG was ﬁrst suggested by
Stegmeier et al.20 (see also Introduction). As already implied by theerapy: Nucleic Acids Vol. 14 March 2019 359
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between the promoter and the miRNA hairpins; however, constructs
with a spacer on 30 of the hairpin have also been described.23 Our
study clearly demonstrates that spacer activity is most efﬁcient
when placed between the promoter and hairpin. Importantly, how-
ever, our data refute the concept that the spacer is simply a spatial
separator. Indeed, as shown in Figure 2, the length of the spacer
does not predict its efﬁciency.Whereas the GFP coding sequence pro-
vided a high-level knockdown, a CD4 intronic sequence led to poor
miRNA expression and therefore knockdown efﬁciency. The
apparent superiority of coding sequences over the intronic sequence
might suggest that translation of the coding sequence was required for
spacer activity; however, this was also refuted by the experiments with
the stopGFP construct (Figure 4). Another possible explanation
would be an impact of the spacer on the stability of the miRGE tran-
script. Our results do not favor this hypothesis. Indeed, we show that
the spacer sequence enhances the steady-state level of miRGE without
any effects on its half-life (Figure 5). Thus, the spacer most likely im-
pacts transcription of the miRNA hairpin. The predicted MFE of the
respective spacer sequences was not correlated withmiRNA efﬁciency
and knockdown, suggesting that the secondary structure of the tran-
script is not crucial (Figure S1A). It is possible that certain biophysical
properties of the spacer are of importance; indeed, there was a ten-
dency (albeit not statistically signiﬁcant) for a correlation between
the spacer GC content and SMIG knockdown efﬁciency (Figure S1B).
It is, however, also worth considering the possibility that spacer nucle-
otide sequence might be of importance. Certain nucleotide motifs
could enhance or limit miRNA transcription and thereby steady-state
levels of the SMIG transcript. Indeed, genes such as human BRCA1,34
mouse c-fos,35 or human c-Myb36 exhibit transcription repression
motifs within their ﬁrst intron sequence; such a mechanismmight ac-
count for annihilation of SMIG knockdown when using the CD4
intron as spacer. Note also that inhibition of miRNA activity by an
intronic sequence has been reported previously.37 Thus, one might
formulate a working hypothesis, where biophysical properties (e.g.,
GC content) optimize spacer activity, and where sequence motifs
(e.g., found in intronic regions) lead to an inhibitory effect. Such a
theory, although still speculative, would be supported by our spacer
truncation experiments. Whereas truncated forms of efﬁcient spacer
GFP exhibited the same knockdown potency as the full-length
variant, truncation of the “inhibitory” CD4 intron spacer led to a par-
tial recovery of SMIG activity (Figure 2C).
Another key ﬁnding of our study is the dissociation of the impact of
SMIG design on single hairpin knockdown efﬁciency versus concat-
enation potential. For example, in the absence of a spacer, the elonga-
tion factors promoter provided an acceptable single hairpin knock-
down; however, concatenation potential was entirely lost under
these conditions. Similarly, the use of the MGST2 spacer within an
SMIG provided an acceptable single hairpin knockdown, but led to
a loss of concatenation potential (Figure 3C). On the other hand,
despite rather poor knockdown with a single hairpin construct, the
H2B spacer sequence allowed efﬁcient concatenation of up to three
hairpins (Figure 3D). Although our studies are the ﬁrst analysis360 Molecular Therapy: Nucleic Acids Vol. 14 March 2019comparing single hairpin knockdown with concatenation potential,
certain previous studies retrospectively corroborate our results. For
instance, when using the Blasticidin resistance gene as a spacer for
miRNA, no concatenation potential was observed.28 Hu et al.29 re-
ported no spacer requirement for the efﬁciency and concatenation
potential of a CMV promoter-driven SMIG. This is in contradiction
with other studies using the CMV promoter.20,23 We think that this is
most likely explained by the fact that the study by Hu et al.29 used
large copy number transfection of the miRNA, which could mask
the spacer requirement when target cells are transduced. Indeed, all
studies using CMV promoter-driven SMIG with a low copy number
vector transduction have consistently reported the use of spacer se-
quences.20,23 In our study, the stopGFP spacer allowed concatenation
of up to ﬁve hairpins without loss of activity of any of the hairpins.
Interestingly, maximum CCR5 knockdown required only three
miRGE hairpins. This suggests that the endogenous miRNA pathway,
including processing by DROSHA, DICER, EXPORTIN5, and RISC,
is not oversaturated with CCR5 hairpins, but rather that CCR5 rea-
ches a background expression level and cannot be further knocked
down. Note that the potency of the different knockdown sequences
was markedly different. Although a single CCR5 knockdown hairpin
could achieve up to a 50% decrease in CCR5, the single GFP knock-
down hairpin decreased GFP expression at best by 20%. These
different knockdown efﬁciencies were not related to SMIG architec-
ture, but simply to the efﬁciency of the targeting sequence.
In summary, we describe an optimized architecture for an SMIG. We
demonstrate that miRNA expression from at least two different poly-
merase II-dependent promoters is highly dependent on the presence
of a spacer sequence, preferably located on the 50 of the miRNA. The
spacer sequence enhances miRNA steady-state levels without a
detectable impact on RNA stability. The biophysical properties and/
or sequence of the spacer, rather than its length or its secondary struc-
ture, seem to be of crucial importance. The expression of up to ﬁve
hairpins can be achieved with this system through concatenation,
allowing efﬁcient targeting of several genes. This multi-target gene
knockdown feature of optimized SMIG constructs is of major thera-
peutic interest. We also demonstrate that the use of our system is not
limited to cultured cell lines. We achieve efﬁcient gene knockdown in
a complex organ such as the cochlea, as well as in vivo in leukocytes
derived from transplanted HSCs. Thus, our results not only provide
novel insights into miRNA expression systems, but also provide novel
tools for the investigation of functional genomics and for therapeutic
applications.
MATERIALS AND METHODS
All animal experimental procedures were conducted under approved
protocol of the local veterinary ofﬁce, authorization number ZH181/
17 and BE 124/13.
Construction of miRNA-Containing Plasmids and Lentiviral
Vectors
The plasmids were constructed using the gateway system as described
previously.14 With the exception of MGST2, spacer sequences were
www.moleculartherapy.orgampliﬁed by PCR using Herculase II polymerase (Agilent, Santa
Clara, CA, USA) with forward and reverse primers carrying, respec-
tively, EcoRI and XhoI restriction sites and cloned into a pENTR
vector (Invitrogen) by digestion and ligation steps (Table S2). Most
of the primers used for the cloning of spacers were designed with
AttB1 (forward primer) and AttB2 (reverse primer) recombination
sites at the 50 extremity (Table S4). The MGST2 spacer was obtained
from pOTB7-MGST2 plasmid (transomic) by EcoRI/XhoI restriction
digestion and subsequent ligation into the pENTR vector. mirGE
hairpins were ampliﬁed using the same strategy and forward and
reverse primers carrying, respectively, SpeI and BamHI restriction
sites. miRGE hairpin concatenates were made using different couples
of restriction enzymes on the miRGE primers or by blunt ligation as
in Sun et al.23 Each new miRGE addition was veriﬁed by sequencing
the pENTR vector. The amplicon parts of each clone, including spacer
and miRGE hairpins, were systematically veriﬁed by sequencing. The
oligos for the miRGE PCR template and primers were obtained from
Microsynth (Balgach, Switzerland). miRGE hairpin template se-
quences targeting CCR5, GFP, and p22phox are available in Table
S3. The ﬁnal lentivector plasmid was generated by an LR Clonase II
(Invitrogen, Carlsbad, CA, USA)-mediated recombination of a
pENTR plasmid containing the human UBI promoter (pENTR-L4-
UBI-L1R) or the elongation factor 1 short promoter (pENTR-L4-
EFs-L1R) and a lentivector destination cassette (pCWX-R4dEST-
R2-PC) containing an additional transcription unit encoding for
mCherry marker gene upon human PGK promoter. The GFP target
sequence, 50-AAGAACGGCATCAAGGTGAACT-30, was taken
from a previous publication.38 The human CCR5 (GenBank:
NM_000579.3) target sequence (T7) 50-aAGTGTCAAGTCCAATC
TATGA-30 was previously used.14
Lentiviral Vector Production and Titration
Lentiviral vector stocks were generated using transient transfection of
HEK293T cells with the speciﬁc lentivector transfer plasmid, the
psPAX2 plasmid encoding gag/pol, and the pCAG-VSVG envelope
plasmid, as previously described.17,18 Lentivector titration was
performed using transduction of HT-1080 cells followed by ﬂow cy-
tometry quantiﬁcation of mCherry+ cells 5 days after transduction, as
previously described.17,18
Cell Culture and Knockdown Analysis
All cell lines were cultured in high-glucose DMEM (Sigma) supple-
mented with 10% fetal calf serum, 1% penicillin, 1% streptomycin,
and 1% L-glutamine. For each knockdown assay, cells were analyzed
at least 5 days after transduction. For CCR5 knockdown studies, a
subclone of HeLa-derived TZMbl cells (AIDS Repository, German-
town, MD, USA), expressing high levels of human CCR5, named
here HeLa R5, was used. For GFP knockdown, the same cells were
used after GFP transduction at one copy of the vector and sorting
of the GFP-positive cells. CCR5 expression was detected using an
anti-human CCR5-allophycocyanin (APC) antibody (Cat. 550856;
BD Pharmingen) and ﬂow cytometry analysis using ﬂuorescence-
activated cell sorting (FACS) Cyan (Beckman Coulter). GFP expres-
sion was assessed on the same ﬂow cytometer using GFP ﬂuorescencemedian. In brief, HeLa cells were transduced at 0.2 MOI with the
miRGE-based knockdown vector to avoid the presence of a high
copy number of the vector per cell and to obtain comparable
conditions. GFP or CCR5 expression was compared between the
transduced and the remaining untransduced population of cells and
expressed as a percentage of CCR5 expression relative to the untrans-
duced population.
Real-Time qPCR
Cells or organotypic explant of organ of Corti were harvested and
mRNA was extracted using QIAGEN RNeasy mini kit following
the manufacturer’s instructions. RNA concentration was determined
using a NanoDrop. 500 ng was used for cDNA synthesis using Takara
PrimeScript RT reagent Kit following manufacturer’s instruction.
Real-time PCR was performed using SYBR green assay on a
7900HT SDS system from ABI. The efﬁciency of each primer was
veriﬁed with serial dilutions of cDNA. Relative expression levels
were calculated by normalization to the geometric mean of the two
housekeeping genes GAPDH and EF1a and the GAG lentivector
gene. The highest normalized relative quantity was arbitrarily desig-
nated as a value of 1.0. Fold changes were calculated from the quotient
of means of these normalized quantities and reported as ±SEM. Se-
quences of the primers used are provided in Table S1.
Real-Time qPCR for Mature miRNA Detection
HeLa R5 cells were transduced at 0.2 MOI with lentivectors carrying
the different SMIGs. Transduced population (expressing mCherry)
was sorted by FACS resulting in a homogeneous cell population car-
rying a single copy of the vector per cell. Total RNA was extracted
using TRIzol Reagent (Ambion) according to the manufacturer’s in-
structions. RNA concentration was determined using a NanoDrop.
One hundred nanograms of RNA was used for the reverse transcrip-
tion (miRCURY locked nucleic acid [LNA] miRNA PCR, polyadeny-
lation and cDNA synthesis kit [exiqon]). Reverse transcription was
followed by real-time PCR ampliﬁcation (ExiLENT SYBR Green
master mix kit [exiqon]) with LNA-enhanced primers. Relative
expression levels of the mature miRGE were calculated by normaliza-
tion to the geometric mean of the two housekeeping miRNA (U6 and
RNU5G). Fold changes were calculated from the quotient of means of
these normalized quantities and reported as ± SEM. Sequences of the
LNA-enhanced primers were not provided by the manufacturer.
ROS Measurement by Amplex Red Assay
PLB-985 cells were cultured in RPMI medium (GIBCO), transduced
as described above, and differentiated into neutrophil-like cells dur-
ing 5 days in the presence of 1.25% DMSO. Levels of H2O2 produced
by intact PLB-985 cells after stimulation of NOX2 with 100 nM phor-
bol myristate acetate (PMA) were then measured using Amplex Red
ﬂuorescence as previously described.39 Fluorescence was measured
with a FluoSTAR OPTIMA, BMG LABTECH instrument at 37C.
Organotypic Culture and Transduction of Rat Organ of Corti
Three-day-old Wistar rats were decapitated and the heads were cut
sagittally to remove the brain. The two otic capsules were isolatedMolecular Therapy: Nucleic Acids Vol. 14 March 2019 361
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(Invitrogen, USA) for sterile dissection under a binocular microscope
(Nikon SMZ800; Japan) with forceps (World Precision Instruments,
USA). After bone removal, the cochlea was transferred to a Transwell-
Clear insert (six-well format; Corning, USA) with a permeable poly-
ester membrane (0.4-mm pore size). The membranes were pre-coated
with Celltak (Corning, USA) according to the manufacturer’s proto-
col. The organ of Corti was then separated from stria vascularis and
the modiolus and plated on the insert, with the hair cells facing up.
Dissection medium was carefully removed, and 1.5 mL of otic culture
medium (DMEM/F12 [Invitrogen, USA], 0.01% ampicillin [Sigma,
USA], and 10% fetal bovine serum [Invitrogen, USA]) was added to
the lower compartment under the insert membrane. On the following
day, the medium on the insert was removed and they were transferred
into an empty well. For the transduction, 200 mL of otic culture
medium was added on the explant together with 70 mL of DMEM/
F12 (Invitrogen, USA) containing 106, 5  106, or 107 particles of
the stopGFP triple miRGE hairpin lentivector targeting p22phox.
After 30 min of incubation at 37C and 5% CO2, 1.5 mL of otic
culture medium was added to the lower compartment. The medium
was replaced with fresh otic culture medium on the following 2 days.
Five days after the initial transduction, cochlear explants were either
detached with trypsin for mRNA isolation or ﬁxed for 10min with 4%
paraformaldehyde for immunostainings.
Immunostaining and Confocal Microscopy of Rat Organotypic
Culture of Organ of Corti
Cochlear explants were ﬁxed with 4% paraformaldehyde for 10min at
room temperature. Explants were transferred (by cutting the insert
membrane) to a 24-well plate, washed three times with PBS, and per-
meabilized with 3% Triton X-100 for 30 min. Cochlear explants were
immersed in a blocking buffer containing 2% BSA and 0.01% Triton
X-100 for 1 h at room temperature. Explants were incubated with the
anti-MyoVIIa (1:500, rabbit; Proteus, USA) antibody in blocking
buffer overnight at 4C. On the following day, tissues were rinsed
three times with PBS and incubated with the secondary antibody
anti-rabbit Alexa Fluor 488 (1:500; Invitrogen, USA) in blocking
buffer for 2 h at room temperature. Explants were again washed three
times with PBS and mounted on a glass slide with Fluoroshield con-
taining DAPI (Sigma-Aldrich, USA). The labeled cells were visualized
with a confocal laser-scanning microscope (Zeiss LSM710) equipped
with a charge-coupled device (CCD) camera (Leica Microsystems)
with a Planapochromat 10/0.3 NA objective.
Knockdown of CCR5 in Humanized Mice Leukocytes
Human CD34 isolated from cord blood using magnetic beads (Milte-
nyi) were cultivated in activation medium (Cell Gromedium contain-
ing 20 ng/mL recombinant human [rh] stem cell factor (SCF), 20 ng/
mL rh Flt3-L, 20 ng/mL rh interleukin-3 [IL-3], 20 ng/mL rh TPO1,
1% v/v penicillin-streptomycin [Penstrep]). The cells were seeded in a
24-well plate at 1.0 106 cells/mL for24 h at 37C in activationme-
dium for pre-stimulation. On the next day for transduction, Lenti-
blast B was added to the medium in a dilution of 1:1,000. Used
MOI for transduction was 50. One well with 0.1  106 cells was not362 Molecular Therapy: Nucleic Acids Vol. 14 March 2019transduced and served as negative control. CD34 cells were cultivated
for 48 h and then harvested except the transduction controls. The cells
designated for transplantation were frozen and stored until transplan-
tation of newborn NGS mice in liquid N2. Newborn NGS mice were
then irradiated with 1 Gy and then transplanted with 260,000 CD34+
cells. Week 23 after birth, engraftment check was done by analyzing
peripheral blood from the mice. CCR5 expression was then investi-
gated at 28 weeks old using the following antibodies: huCD45 FITC
(304006), CD3 AF700 (300424), CD4 PE-CY7 (300512), CD8
BV421 (301036), and CCR5 APC (359122) (or isocontrol #400611)
from BioLegend.
Prediction of the MFE of Spacer Sequences
The MFE of spacers was calculated using RNA fold web server
(Institute for Theoretical Chemistry, University of Vienna; http://
rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). To allow
comparison of MFE between spacers, obtained values were divided
by the length of the spacer.
Calculation of the Efficiency of Concatenation of Triple Hairpin
Concatenates
The concatenation efﬁciency of triple hairpin constructs (E) was
calculated according to the formula E = ln(CP)/ln(KP), where KP
and CP are, respectively, the knockdown of CCR5 obtained with sin-
gle and triple hairpin constructs. If E = 3, a fully additive effect of the
hairpins is observed in the concatenate. If E = 1, the triple hairpin
construct is as efﬁcient as the single hairpin construct, and no additive
effect of the hairpins concatenation is observed.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5.04
(GraphPad Software, La Jolla, CA, USA). We used one-way
ANOVA followed by Bonferroni’s multiple comparison tests, as
well as t tests (non-parametric, Mann-Whitney U test).
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